Pharma producer chooses Maersk’s services to reduce transportation carbon footprint
AP Moller-Maersk recently announced the signing of a logistics agreement with Danish pharmaceutical company Novo Nordisk from 2021. The three-year agreement on cold chain logistics covers transportation including ocean services and inland logistics.
“Transporting pharmaceuticals on a global level is a demanding task with various complexities that require flexible and resilient supply chains as well as digital and eco-friendly solutions. This achievement showcases the rapid transformation of AP Moller-Maersk as a modern end-to-end logistics company with fully controlled assets,” commented Vincent Clerc, Executive Vice President and CEO, Ocean and Logistics, AP Moller-Maersk.
One of the largest pharmaceutical companies in the world, Novo Nordisk has chosen Maersk´s ECO Delivery to reduce the carbon footprint in transportation. The initiative uses sustainable bio-fuel to power selected Maersk-vessels and helps Novo Nordisk to make progress towards its ambitious sustainability goals.
“Our ambition of achieving zero environmental impact is a cornerstone of our aspiration to be a truly sustainable business. We consider AP Moller–Maersk to be the right global distribution partner to secure the steady, environmentally friendly delivery of our high-value shipments and we look forward to the collaboration,” remarked Rune Sylow, Corporate Vice President, Strategic Sourcing, Novo Nordisk.
The global agreement will be effective from1 April 2021.
